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Co-infection of men who have sex with men who have sex with men (MSM) with 
HIV and and Neisseria gonorrhoeae/Chlamydia trachomatis (NG/CT) remains a 
significant public health problem in the United States due to co-infection dynamics 
creating an epidemiologic phenomenon whereby co-epidemics of HIV and NG/CT (along 
with other STIs) help propagate each other. One of the key components of the US 
National AIDS Strategy revolves around the HIV Care Continuum, in which HIV 
infected persons are diagnosed, linked to care, retained in care and virally suppressed to 
prevent transmission. Screening for HIV is the entry point for the care continuum and 
various understanding the most efficacious strategies for this is of utmost importance to 
help identify HIV infected persons and link them to care. We used an agent-based model 
to test three screening strategies for efficacy: targeting high risk MSM, increased general 
HIV screening, and improved NG/CT screening amongst HIV infected MSM.  
Targeting high risk MSM and increased general HIV screening produced 
significant decreases in the HIV and NG/CT incidence relative to baseline; but the former 
produced steeper declines while simultaneously testing thousands less persons. Improved 
NG/CT screening amongst HIV infected MSM has no impact on the incidence rate of 
either. The targeting high-risk MSM strategy produced steep declines in HIV incidence, 
and efficiently achieved this in less HIV tests given per year compared to the general 
HIV screening. This suggests that targeting high risk MSM may be a more effective 
approach to achieve reduction in HIV incidence. Furthermore it suggests that the HIV 
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Co-infection of men who have sex with men who have sex with men (MSM) with HIV 
and and Neisseria gonorrhoeae/Chlamydia trachomatis (NG/CT) remains a significant 
public health problem as this results in increased transmissibility of these diseases. HIV 
infection is a particularly large problem in Baltimore City, which has one of the highest 
rates of HIV in the US at 7 times the national average.57 HIV transmission is further 
modified by co-epidemics of other sexually transmitted infections (STIs.)33 HIV/STI co-
infected individuals are more likely to transmit the disease, and STI infected individuals 
are more likely to acquire HIV.33 HIV, chlamydia, and gonorrhea, infections particularly 
impact men who have sex with men (MSM). Per the Centers for Disease Control (CDC) 
guidelines, sexually active MSM should be screened for Neisseria 
gonorrhoeae/Chlamydia trachomatis (NG/CT) at least every year, and every 3-6 months 
if at higher risk (e.g. infected with HIV).58 Yet in Baltimore, this annual screening rarely 
reaches 40%.24 Once a person is diagnosed with NG/CT, they given a one-time treatment 
of antibiotics to cure and clear the infection.  
Gonorrhea infection has been shown to be associated with an increased risk for 
HIV aquisistion.59 Several studies have suggested that coinfection with HIV, gonorrhea 
and syphilis increase viral load, and subsequently viral shedding, resulting in increased 
risk of HIV transmission by co-infected individuals.60 Furthermore, gonorrhea and 
chlamydia infection can enhance the risk of HIV acquisition via inflammation, disruption 
of the genital mucosa and increased numbers of active immune cells.61 While gonorrhea 
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and chlamydia are non-ulcerative STIs (whereas ulcerative STIs increase the risk of HIV 
transmission and acquisition more substantively), it has been posited that the far greater 
prevalence of these two STIs in the general population makes them potent modifiers of 
HIV transmission dynamics, particularly amongst MSM.61  Gonorrhea and chlamydia 
infection have been found to statistically significantly increase the odds of HIV 
acquisition by 1.8, creating an epidemiologic phenomenon whereby co-epidemics of HIV 
and NG/CT (along with other STIs) help propagate each other.62   This in turn suggests 
that measures to combat one of these diseases may in turn decrease the incidence of the 
other.  
Furthermore, some of the key HIV prevention strategies involves encouraging 
safe sex practices (e.g. condom use), behavioral change, pre-exposure prophylaxis (PrEP) 
and treatment as prevention (TasP) via highly active antiretroviral therapy (ART). 63–66 
Getting persons engaged in HIV care and treatment is critical for both preventing 
progression to AIDS amongst HIV-positive individuals and preventing the spread of HIV 
within a population via the TasP strategy. Once a person is diagnosed with HIV infection, 
the goal is link the patient to care providers, prescribe the patient antiretrovirals (ART), 
have the patient adhere to ART, and retain them in care. This pathway from diagnosis, to 
treatment, to retention, to maintained viral suppression is referred to as the HIV Care 
Continuum.67,68  As such, increasing knowledge of HIV status, linking and retaining those 
infected in care, and improving drug adherence is critical to controlling the disease in 
populations. Particularly, screening for HIV and subsequent diagnosis is important since 
it is the entry point to the care continuum. However, there is some debate as to the best 
way to increasing screening and outreach in the MSM.69 Often, the approach is to use 
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general HIV “know your status” screening events, which aim to increase general uptake 
of HIV screening in communities. Given that certain sub populations of MSM can be 
prone to higher risk and higher transmission of HIV, targeting these populations for 
increased screening may prove more effective. Conversely, given co-infection dynamics 
of NG/CT and HIV that suggest they may help increase transmission of the other; 
improved NG/CT screening amongst HIV infected MSM may also be an effective 
targeted screening strategy to link persons to the care continuum.  
HIV Natural History and Epidemiology in the United States  
 
HIV is the second largest cause of death by an infectious disease in the world. In 
the United States, HIV is not a major cause of mortality, but a significant cause of 
morbidity. HIV is most commonly transmitted via sexual intercourse; however, 
transmission can also occur vertically from mother to child, via blood transfusion, and 
through contaminated needles.70 Several key populations are at higher risk for HIV 
acquisition due to social and biological factors, chiefly sexual behavior.71 When a person 
is initially infected with HIV the virus enters the acute phase. HIV infects cells presenting 
the molecule CD4 on the surface, using CD4 along with other cell surface molecules to 
enter the cell and replicate. Initially the immune system is able to control the infection, 
leading to a reduction in viral load and a slight increase of CD4 T cells.71  However HIV 
then enters a stage where it infects CD4 cells at lower levels that do not trigger an 
extensive immune response.71 As HIV kills more CD4 T cells, the body’s ability to 
mount an adaptive response to the virus is diminished and viral load begins the climb.  If 
CD4 count falls below 200 cells/ml, the person develops AIDS, and has great difficulty 
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mounting an immune response against any invading pathogen.71 In the absence of 
treatment, this can lead to death from an opportunistic infection and a range of other 
debilitating symptoms.   
In the US, HIV is quite prevalent but not a significant cause of mortality any 
longer.67 Current US HIV/AIDS policy is driven mostly around the HIV Care Continuum 
and preventing new infections. The 2015 update to the United States National HIV-AIDS 
Strategy has ambitious goals, including: increasing serostatus awareness among those 
living with HIV to 90%, reducing the number of new diagnoses by 25%, increasing to 
85% the number of persons linked to HIV care within one month of their diagnosis, 
increasing the percentage of persons retained in HIV care to 90%, and increasing the 
percentage of persons diagnosed with HIV who are virally suppressed to 80%.67. Per 
NHAS, the goal is “The United States will become a place where new HIV infections are 
rare, and when they do occur, every person, regardless of age, gender, race/ethnicity, 
sexual orientation, gender identity, or socio-economic circumstance, will have unfettered 
access to high quality, life-extending care, free from stigma and discrimination.”67 The 
HIV care continuum is an integral part of this strategy, and the collaboration across the 
federal government is critical to improve each step of the HIV Care Continuum.24 While 
the care continuum is just part of the overall plan (with other areas focused on behavioral, 
social, and educational interventions to prevent new HIV infections), it is a key 
component to assist persons already living with HIV and to reduce their chances of 
transmitting the infection to others.67,68  The report also notes that STI clinics are where 
many people get tested and receive their HIV diagnosis; 1 in 10 MSM receive their HIV 
diagnosis within one year of being diagnosed with rectal gonorrhea and syphilis.67 
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Understanding how the STI clinic plays a role in linking MSM to HIV Care and the 
overall Care Continuum will help illustrate how the clinic plays a role in, and reduces 
barriers to, this linkage to HIV care.  
Barriers to the HIV Care Continuum include late HIV diagnosis, suboptimal 
linkage to care, poor retention in HIV care, poor ARV adherence, viral resistance to ARV 
medications, and insufficient use of ARVs.72 Understanding and reducing the impact of 
these barriers is paramount to increasing the percentage of persons knowing their 
serostatus, engaged in care, and achieving viral suppression. Recent data suggests that in 
serdiscordant couples, ARV-achieved viral suppression has reduced the risk of HIV 
transmission from 92-98%, illustrating the importance of archiving viral suppression in 
HIV-infected individuals.68  However, improving engagement in just one area of the care 
continuum doesn’t have a major impact at the other levels; therefore, improvement across 
multiple, if not all levels is paramount to strengthening the care continuum.68,72 
In the US, it is estimated that 1.2 million people are living with HIV, and of these, 
13% do not know they were infected.67  As previously noted, Baltimore has some of the 
highest rates of HIV and STI’s in the United States.57 In 2010 (the most recent publicly 
available data) the rate of new HIV diagnoses in Baltimore (77.6 per 100,000) was 7 
times the national rate (16.3 per 100,000), and 3 times the Maryland rate (30.0 per 
100,000). 57 In Maryland, the vast majority of HIV cases are concentrated in Baltimore, 
and HIV/AIDS is still a top 5 cause of death for adults in the city. 57 In 2012, the among 
men infected with primary and secondary syphilis , 60.1% were also co-infected with 
HIV. 57 HIV transmission in Baltimore is also highly concentrated amongst African-
American MSM. 57 
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Chlamydia and Gonorrhea Natural History and Epidemiology in the United States. 
Chlamydia trachomatis and Neisseria gonorrhea are the most common bacterial sexually 
transmitted infections in the US. The majority of infections are asymptomatic, 
highlighting the importance of screening programs in reducing population chlamydia 
burden.73 Transmission for both occurs during vaginal, anal, and oral sex and contact 
with infected tissues. Once a person is infected, chlamydia can establish a long term 
infection, with 50% of infected persons clearing the infection within one year, 80% 
within 2 years, and 90% within 3 years.74 The immune response for Chlamydia typically 
involves neutrophil and monocyte mucosal infiltration and inflammation, which can 
result in long-term tissue damage and scarring in the event of persistent infection.75,76 
Chlamydia has several different clinical manifestations unique to men. These include 
urethritis, epididymitis, prostatitis, and proctitis, the latter of which is particularly 
common amongst MSM who have unprotected anal intercourse (UAI).73  In the absence 
of treatment proctitis can result in fever, anorectal pain and discharge, bleeding, and 
constipation. These symptoms also increase the potential for transmission, though are not 
required.73,75  
Gonorrhea pathogenesis proceeds in 4 stages, attachment to the mucosal surface, 
local penetration and invasion, local proliferation, and lastly local inflammatory response 
or system distribution.77 Neisseria gonorrhoeae has high levels of antigenic variation, 
which can make it difficult for the immune system to mount a specific response.77,78 
Antibiotic resistant Neisseria gonorrhoeae has also been reported, further complicating 
treatment and control. Urethritis is the most common symptom, though many cases are 
 7 
asymptomatic.78 Persons who are asymptomatic can transmit the bacterium to an 
uninfected partner.79 On average about 50% of persons exposed to an infected male 
partner become infected, with that percentage rising to 93% with repeated 
exposures.80Gonorrhea and chlamydia often co-infect individuals in many 
populations.73,75 
There exist several NG/CT tests, with the gold standard being nucleic acid 
amplification tests (NAATs), e.g. polymerase chain reactions (PCR).73,75 Other tests 
include serology, antigen detection, and bacterial culture.6 Screening for chlamydia is 
critical for disease control because of the high proportion of asymptomatic cases, the 
potential for long term infection, and the potential for re-infection with the causative 
organism.75 Most public health programs regarding chlamydia prevention involve 
interrupting transmission by encouraging safe sex practices, and diagnosing and treating 
chlamydia cases can help achieve this goal.75 
Chlamydia is the most commonly reported notifiable disease in the United States, 
with 1,526,658 cases reported in 2015, and rates increasing in recent years.81  The overall 
prevalence of chlamydia in the population aged 14-39 years old was 1.7%.81  Among 
MSM in the United states, the prevalence of chlamydia was 16%, and about 17% in 
Baltimore, illustrating the importance of targeting screening and prevention strategies this 
population. 10  
Furthermore, in the US in 2015, there were 395,216 cases of gonorrhea, with an 
overall rate in men of 140 cases per 100,000 persons 82 Amongst MSM, this rate was 
1,474.4 cases per 100,000 MSM in 2013.83 This difference in rates amongst men overall 
compared  to the much higher rate amongst MSM alone, illustrates the disproportionate 
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burden of gonorrheal disease in MSM. In Baltimore, the prevalence of gonorrhea 
amongst MSM was 16.9%, which was in fact the lowest prevalence of gonorrheal disease 
amongst STI surveillance network sites. 82  Even with its relatively low prevalence, almost 
1 in 5 MSM in Baltimore are infected with gonorrhea, illustrating a high burden of 
disease in this subpopulation. Given the complex epidemiological and biological 
interactions between gonorrhea, chlamydia, and HIV and the high burden in the MSM 
population in Baltimore, better understanding of the transmission dynamics and 
opportunities for control measures to be implemented is of the utmost importance.   
Social and Epidemiological factors impacting HIV and STI transmission in MSM 
populations  
 Social factors impacting MSM transmission include high number of sexual 
partners, seroadaptive behaviors, ethnicity, and stigma. MSM can have higher number of 
sexual partners; thus magnifying their risk of acquiring HIV though multiple potentially 
infectious contacts. 38 This risk can be compounded by a behavior known as “bare 
backing” which is defined as deliberate avoidance of condom use.84 This can lead to 
someone being infected more easily, and then spreading infection to others, which can 
speed the spread of HIV though a sexual network. 84 Furthermore, HIV is more common 
amongst ethnic minorities. In the US, black MSM are much more likely to become 
infected with HIV, not know their serostatus, and not be linked to healthcare because of 
economic and social factors limiting healthcare access. In turn, black MSM, compared to 
other MSM can be more likely to be living in poverty, be less educated, and more likely 
to be incarcerated.84 Indeed, this in turn leads to black MSM also having less access to 
STI/HIV prevention education and items that could reduce the chance of infection, eg. 
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condoms.84 Furthermore, MSM overall can be a stigmatized minority, which can make 
health care access and outreach challenging, and require extra effort in order to reach that 
community. MSM in certain regions of the United States, and the world, may be afraid to 
come forward and seek medical attention for fear of this identifying them as MSM.38,84  
Combatting these socio-structural barriers to health access is important to also help 
combat HIV. 
Baltimore City HIV and STI Prevention  
 The Baltimore City Health Department (BCHD) operates 2 public STI clinics that 
offer STI/HIV counseling and care. These facilities offer both rapid (results delivered less 
than 30 mins) and conventional testing. If one tests positive, the person is offered 
confirmatory testing, partner services and linkage to primary care. In 2010, amongst 
persons attending these STI clinics, 89% of HIV positive persons them received at least 
post-test counseling. 57  BCHD also encourages local emergency departments (EDs) to 
screen for HIV and other STIs. 57 BCHD also screens via community based health 
organizations, such as Chase-Brexton Healthcare, which is the largest provider of health 
services to the MSM community in Baltimore. 57 BCHD has used syphilis 
epidemiological data to help direct where they should concentrate their HIV testing 
efforts. 57 Some locations beyond EDs and STI clinic’s BHCD tests at are methadone 
clinics, LGBT events and homeless shelters, all provide providing to further link identify 
HIV infected persons and link them to care. 57 The Maryland Department of Hygiene and 
Mental Health (DHMH) issued a series of regulations aimed increasing the detection of 
HIV, via a new opt-out policy (as opposed to opt-in) whereby healthcare practitioners in 
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a range of settings offer diagnostic HIV testing and HIV screening as a part of routine 
clinical care for individuals ages 13-64. 57 
 Once a person is diagnosed with HIV, they are offered post-test counseling and 
are linked to care. Care-Linkage Investigators (CLIs) will make phone-calls and field-
visits to HIV infected persons to help them find care and partner-services. 57 Often, many 
efforts are made to locate clients after they test positive, but sometimes they are lost to 
follow up. This linkage to care initiative is part of the BCHDs Early Intervention 
Initiative. 57 To incentivize clients to show up for their second appointment, they are 
offered gift cards. The linkage to care strategy is as follows; 1) BCHD searches existing 
STI/HIV databases if the person has previously tested to understand their needs and 
potential services. 57 2) Each person is prioritized in terms of the following a) knowledge 
of their HIV status, b) prior access to HIV partner counseling and referral services, and c) 
documentation of previous access to primary care. 57 3) New clients are assigned a 
counselor who notifies them of their test results, offers them partner services and outlines 
their care options and where to receive care (eg. primary, and Ryan White funded 
services). 57 4) Previously identified clients are assigned CLIs who help link the person to 
primary care. 57 5) The persons are added to the STI-MIS database for documentation and 
data collection. 57 
Modeling STI and HIV Screening Strategies and Their Effects on the Epidemic  
Agent based modeling is a method that attempts to simulate the interactions and 
actions of autonomous agents within a group to determine how these individual actions 
translate to macro-level effects. These models have several levels including individual 
agents who have certain actions/behavior patterns (e.g. an MSM who is in a monogamous 
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relationship), decision making and learning process for these agents, interaction rules, 
and an overall environment. Randomness is introduced to the model via Monte Carlo 
methods. The value of agent-based models is that they attempt to infer and predict 
complex behaviors and their macro-level effects from the collective effect of individual 
simple decision-making.   
Screening for HIV and NG/CT are critical components to their control strategies. 
However, simply having general HIV or NG/CT screening might not be the most 
impactful approach to identify cases of these diseases; and linking those infected to care. 
Given the epidemiologic interaction between HIV transmission and NG/CT co-infection, 
and that being screened for NG/CT likely increases treatment uptake, simply meeting the 
CDC screening guidelines could have a significant impact on both the NG/CT and HIV 
epidemics in Baltimore city. This could lead to higher detection and treatment of NG/CT 
cases; and subsequently decrease the incidence of these diseases.  Furthermore, MSM 
who are at high-risk for HIV and NG/CT infection due to age and sexual activity could be 
major drivers of the epidemic since they can potentially spread the infection to more 
people. Targeted screening in this population and linking infected persons to care could 
also have a significant impact on the HIV and NG/CT epidemics in Baltimore city.  
Conversely, increased screening for HIV and linking infected persons to care could not 
only decrease HIV incidence, but also potentially decrease NG/CT incidence This study 
will explore 3 screening scenarios and their impacts on HIV and NG/CT incidence in the 
MSM population in Baltimore over a 50-year period after their rollout. The scenarios 
explored are: 1) targeted screening of high-risk (defined as young and sexually active) 
MSM for both HIV and NG/CT testing; 2) a general HIV only screening program for 
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persons who present for STI care; and 3) testing the impact of increasing the proportion 
of HIV infected MSM screened for NG/CT and ultimately of meeting the CDC NG/CT 
screening guidelines for this population.  
Methods    
 
Agent Based Model to study MSM, HIV, and STI Outbreaks 
Demographic Module  
 In this model agents are single MSM who are characterized by age, race, and 
neighborhood. Each agent is evaluated at every time step, which in this model is one 
week. At each time step the following are evaluated: the per act probability of HIV 
transmission, HIV testing probabilities, linkage to care probabilities in terms of 
engagement and disengagement, and probability of ART provision/viral suppression 
achieved. Transmission of HIV (modeled as a per sexual act probability) is determined by 
serodiscordant partnership status, frequency of sex act, safety of sex act, HIV stage of 
infected partner, and ART/PrEP use (Table 1).  
 The demography module determines the baseline population structure and 
controls the model procedures for aging, birth and death. The population modeled was 
MSM in Baltimore aged 15 to 75. The population in the model is structured by 
Baltimore’s Community Statistical Areas (CSAs). There are 55 CSA’s in Baltimore. 
Agents’ in the model are defined by their CSA and race (white Caucasian, or Black 
African American.) Agents’ age according to a simulated clock and exit the model based 
off by the age specific mortality rate, upon reaching age 75 or via the increase in 
mortality due to HIV infection. The population is replenished by a birth process which is 
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modelled using Poisson methods calibrated to each CSA’s mean population. New persons 
enter the population at age 15 and are calibrated to CSA. Baltimore’s MSM population 
size was estimated to be about 15000, based off of the population of men in Baltimore 
above the age of 15, and previously published percentages of MSM in the city.85 Racial 
makeup of each CSA was arranged in levels, from 1-5, with each level being the 
proportion of that CSA population that was African American.   
 CSA groupings were made to determine how agents might interact with other 
people from other regions of the city. CSA groupings were determined by sharing a 
border and only differing by income and racial makeup by 1 level. These groupings 
continued by CSA’s of similar status until they came into contact with CSA’s that 
differed by more than 1 level. This procedure was followed for all groupings, and 
eventually 16 groupings were made. These groupings determined how individuals could 
interact and spread throughout the model. 
Partnership Module.  
 
 The second module of the model is the sexual partnerships model which 
delineates how agents can form sexual partnerships There are two types of partnerships in 
the model, “stable” and “casual”. Stable partnerships last for several years, whereas 
casual partnerships last only for a single week. As previously discussed, CSA are placed 
into neighboring groups to determine an agent’s search area. If they are seeking a new 
partnership, agents can search for new partners in their own CSA, in neighboring CSAs 
and non-neighboring CSAs, each with a different probability. These probabilities govern 
the mixing patterns and clustering of sexual partnerships within a CSA, and then this 
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applied across the whole population.  Then once this geographic search domain has been 
made, agents can establish partnerships, which is determined by a probability governed 
by age and race mixing. Individuals search their entire search domain in its entirety, 
potential partnerships are checked for compatibility, and incompatible ones are dissolved. 
Incompatibility is assessed regarding sexual positioning (insertive preference or receptive 
preference). Age mixing and race mixing parameters were based off of the BESURE 
study (The Baltimore branch of the National HIV Behavioral Surveillance System). At 
the end of each simulation week, partnerships are updated, and those who have reached 
their pre-specified duration are terminated.   For those agents whose partnerships 
dissolved, they begin to search for new partnerships based via the geographic search 
domain based on where they live. They will select partners based on race and age-
depending mixing patterns and on sexual role. An agent can engage in multiple casual 
partnerships from week to week, or can only be involved in, at most, one stable and one 
casual partnership at a time. An individual’s probability of seeking out a new partnership 
is a probability based on their age and is fixed by age group. High-risk behavior is 
modeled as a function of age and number of sexual partners. The individual’s sexual role 
preference is fixed at birth. There are also two parameters that govern whether or not an 
induvial will engage in a stable or casual partnership.  
HIV Epidemiology Module 
 
 HIV infection is modeled as 3 disease states, acute infection (CD4 count > 500 
cells/ul ), chronic infection (CD4 count  200-500 cells /ul) and late infection (CD4 count 
< 200 cells/ul). The disease state determines an individual’s CD4 count, mean viral load 
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(which was a measure of infectiousness), and HIV mortality rate. The disease state 
progression assumes the absence of antiretroviral therapy (ART). If an individual is on 
ART, depending on stage they start treatment, they will either remain in the chronic state 
or dwell in the late infection stage for 1 year before reverting back to the chronic stage.  
CD4 count is not modeled directly, but the disease state is based off of viral load, as that 
is a direct measure of infectivity.  
 The HIV continuum of care is modeled in 5 stages: 1) unaware of infection; 2) 
aware of infection status, but not linked to care; 3) linked to care, but not engaged; 4) 
engaged in care and on ART; and 5) engaged in care, but not on ART. At each time step 
HIV-positive persons have a probability for being screened for HIV, and subsequently if 
diagnosed, have a fixed probability of being linked to care. Once these persons are 
engaged in care, they start ART. These same persons, after starting ART, will have viral 
load decrease for the first few months, and then full viral suppression after that period. 
ART also lowers the mortality rate at each disease stage. Persons who start ART at the 
late infection stage (CD4 < 200 cells/ul) will have a mortality rate adjusted for ART for 
one year, before moving back to the chronic state (CD4 200-500 cells/ul). Persons can 
stop being engaged care and adhering to ART, and if this occurs they cannot restart ART 
for 6 months. These persons will also no longer be virally suppressed and experience a 
decrease in CD4 count. At each time step, persons who had disengaged in care, will have 
a weekly probability of restarting care. Persons re-continuing ART can move between the 
disease stages.  
 At each time step, for serodiscordant partnerships, transmission to the negative 
partner is evaluated. This transmission probability is determined by the infectivity (viral 
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load) of the infected partner, the negative partner’s immunity, and the global transmission 
coefficient. The negative partner’s immunity is a measure of their PrEP adherence, which 
is a value ranging from 0 to 1 determined by absence to full adherence to PrEP. The 
global transmission coefficient is a measure of the baseline rate of HIV transmission per 
contact. 
 Sexual role preference is assigned at birth (insertive, receptive, or versatile). Two 
persons who are both insertive or both receptive are considered to be incompatible 
partners within the model. If both partners are versatile, the type of act (receptive or 
insertive) is 50% for each man. The proportions of each sexual preference was calibrated 
by BESURE study data and is as follows: 42% insertive-only, 26% receptive-only, and 
32% versatile. 
Gonorrhea and Chlamydia Epidemiology Module 
 
 Gonorrhea and Chlamydia (NG/CT) in this module are assumed to be spread 
through sexual contact (oral and rectal). The dynamics of infection are modeled as a 
susceptible, infected, susceptible (SIS) model because there does not seem to be any 
protective immunity; therefore, once a person is recovered, they can be re-infected. 
Persons who are infected and have symptoms have a fixed probability of seeking care at 
each time step, and once seeking care, have a probability of being tested for NG/CT. If 
the test is positive, they are treated. Other care seeking episodes for other reasons for care 
will not result in a test and treatment for NG/CT. Persons who are on treatment are 
assumed to be infectious during treatment and for the week after. This type of testing is 
referred to as symptomatic testing behavior. MSM can also be regularly screened for 
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NG/CT as well per the CDCs recommendation based on MSM HIV status. Model 
Calibration  
 The model used BCHD data on HIV and NG/CT cases in Baltimore in order to 
simulate the HIV outbreak in Baltimore city. Parameters (such as incubation, HIV and 
NG/CT interaction, infectiousness, screening etc) were gleaned from a literature review 
and are presented in table 1. From the BCHD dataset, the prevalence of HIV amongst 
MSM is 3329 people. In our simulated MSM population of 15,000, this corresponds to a 
prevalence of 22%.  
 The BCHD dataset for gonorrhea contains all males in Baltimore with gonorrhea 
infection that were reported to the BCHD. These cases were reported between 1/1/09 and 
5/31/16. The cases were restricted from 2011 until 2015 because in 2011, STI clinics 
switched to using the NAAT to diagnose syphilis, which is in line with the CDC’s 
guidelines. Unfortunately, sexual identity was not included for the men in this dataset, 
however, certain persons diagnosed with NG were selected for a (STD Surveillance 
Network) SSuN interview, and amongst this dataset, 26-30% of these men identified as 
MSM.  
 The adjustment for persons not seeking care was based off literature parameters. 
About 60% of symptomatic persons do not seek out care. To account for this, the number 
of cases was increased by 150% to estimate the true number of actual cases. Furthermore, 
to adjust for asymptomatic cases, which would determine care-seeking behavior, the 
proportion of symptomatic cases reported in the literature was used. These proportions 
were 74% symptomatic for urethral, 20% for rectal, and 10% for pharyngeal.  
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 The BCHD data for the proportion of HIV-infected MSM screened for NG/CT is 
40%. To meet the CDC guidelines, this parameter in the model is set at 100%. This will 
model the effects of screening that meets the CDC guidelines regarding annual screening 
for HIV-infected MSM.  
Simulation Calibration  
The BESURE 2014 study provided detailed MSM social and sexual network data that 
was used to calibrate the partner structure in the model. The data included details on the 
average number of partners in  the last 12 months, the type of partners by age-group, and 
stability of the  partnerships to calibrate the proportions in the simulated MSM population 
in the model. 86 The simulation was run 200 times, and from that, the average distribution 
was determined. The parameters for the model are presented in table 1. 
 
Testing for Effects of High Proportions of NG/CT Screening  
 To understand the effects of increased NG/CT screening on both the dynamics of 
the NG/CT epidemic and the HIV epidemic we tested 3 screening strategies with various 
levels of screening for each one. These scenarios were generated by manipulating 3 
parameters in the model, the weekly probability of presenting to STI care and screening 
for HIV and NG/CT for high-risk MSM, the weekly probability of screening for HIV 
infection only in the general MSM population, and the probability of compliance with the 
CDC recommendation among HIV-infected MSM for presenting to STI care every 12 
months and testing for NG/CT infection. The first 2 parameters were manipulated by 
modulating the weekly probability of screening relative to baseline, such that we ended 
up with 3 scenarios, twice (2x) as likely, four times (4x), and 8 times (8x)) for each of the 
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parameters. For the probability of compliance with the CDC recommendation among 
HIV-infected MSM for presenting to STI care every 12 months and testing for NG/CT 
infection parameter, this was arranged a proportion from 0 to 1, with proportions 0.4, 0.6, 
0.8 and 1 as each scenario. This resulted in 4 experimental scenarios plus 1 baseline 
scenario for each of the 3 manipulated parameters, resulting in a total of 12 scenarios. 
Simulated data regarding incidence of symptomatic and asymptomatic NG/CT, 
prevalence of NG/CT in the population, persons screened for NG/CT, prevalence of HIV, 
incidence of HIV, HIV mortality and persons screened for HIV were obtained. The data 
output by the simulation was analyzed to determine the differences between the screening 
scenarios, and the effects on the NG/CT and HIV outbreaks. 
Statistical Analysis 
 Analysis of variance (ANOVA) tests were used to determine the significance of 
difference between each of the scenarios, and the base line incidence or screening 
proportion. Graphs illustrating the trends in HIV incidence, persons screened for HIV, 
NG/CT incidence, and persons screened for NG/CT were generated for each of the 3 




Targeting High-Risk MSM for HIV and NG/CT Screening 
Impact on HIV Epidemic 
4 total scenarios modeling the different impacts of targeted HIV and NG/CT 
screening were generated. These scenarios were the baseline (current scenario in 
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Baltimore) and the following modulated probabilities: twice (2x) as likely to present for 
screening, four times (4x), and 8 times (8x). The baseline scenario had relatively stable 
patterns of HIV and NG/CT incidence; with an average incidence per year of 1440 cases 
per 100,000 persons and 17,393 cases per 100,000 persons for HIV and NG/CT 
respectively. Under baseline conditions the incidence rate fluctuates very little over time. 
Additionally, an average of 6,756 HIV tests, along with an average 3,686 NG/CT tests 
are given annually.  
The impacts of each of these scenarios on HIV incidence are depicted in Fig 1a. 
HIV incidence in the total population decreases over time for all non-baseline scenarios, 
and the magnitude of this decrease increases accordingly by scenario screening 
probability. Fig 1b shows the number of HIV tests given each year. The differences in 
HIV incidence per 15,000 persons per year (the population of the model) at years 10, 20, 
30 and 40 are all statistically significantly different from baseline.  
Further one-way ANOVA tests were completed to determine if there were 
differences between each of the increased screening scenarios to each other. The baseline 
level of HIV incidence amongst MSM in Baltimore in the model was 1,447 cases per 
100,000 persons at year 10. At this same time point, the incidence rate fell to 1407 cases 
per 100,000 persons under the 2x screening scenario, 1380 cases per 100,000 persons 
under the 4x screening scenario, and 1353 cases per 100,000 persons under the 8x 
screening scenario. At year 30, these differences were more pronounced, with the model 
forecasting an incidence rate of 1440 cases per 100,000 persons under baseline 
conditions; and the incidence rate falling to 1373 cases per 100,000 persons under the 2x 
scenario, to 1307 cases per 100,000 persons under the 4x scenario, and 1260 cases per 
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100,000 persons under the 8x scenario. These represent decreases in incidence of 4.65%, 
9.23%, 12.5% over a 30-year period for the 2x, 4x, and 8x screening scenarios 
respectively. 
        All screening scenarios start realizing a significant decline (p<0.001) in HIV 
prevalence after 20 years of continuous intervention.  The 2x screening scenario does not 
start to show significant decreases in prevalence until year 10, and takes longer for the 
steep drop in prevalence to occur relative to the other scenarios, as seen in Fig 2. The 
drops in prevalence can be seen for all screening scenarios starting after 30 years of 
continuous intervention. As expected, the trend of the overall decrease in prevalence is 
mirrored by the increase in screening probability under each scenario. None of the 
scenarios seem to exhibit a plateauing in the prevalence over the first 40 years after 
intervention. HIV incidence is decreased significantly from current baseline levels of 
screening under each of these 3 increased screening of high-risk MSM scenarios, and that 
increasing the likelihood of screening significantly decreases HIV incidence between the 
scenarios as well. 
To achieve these reductions in HIV incidence and prevalence, more MSM had to 
be screened. At baseline roughly 6,756 tests for HIV were given each year. The average 
number of tests for HIV per year jumped to 10,116 under the 2x scenario, 13,437 under 
the 4x scenario, and 16,733 under the 8x scenario. As was expected, the increase number 
of HIV tests in each scenario corresponded with a larger decrease in HIV incidence and 
prevalence. 
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Impact on NG/CT Epidemic 
Figures 3a and 3b depict the impact of increased screening of high-risk MSM on 
NG/CT combined incidence and total screening levels per year. A similar pattern to HIV 
incidence is seen here, with all increased screening scenarios showing decreased NG/CT 
incidence over time, but the extent of the drop in NG/CT incidence is much greater than 
for HIV. The magnitude of the decrease in incidence is mirrored by the increased 
modeled probability of screening. As seen in Fig 3a, doubling the probability of 
screening amongst high-risk MSM has a noticeable impact on NG/CT incidence over 
time; with even greater decreases in incidence over time seen as screening probability 
increases (as modeled by scenario). The differences between NG/CT incidence per 
15,000 persons at Years 10, 20, 30 and 40 are all statistically significant from baseline (p 
< 0.001). Under the baseline conditions at year 10, the rate of NG/CT is 17,387 per 
100,000 persons. In the increased screening scenarios at year 10, the incidence rate is 
16,067 cases per 100,000 persons under the 2x scenario, 14,660 cases per 100,000 
persons under the 4x scenario, and 13,426 cases per 100,000 persons under the 8x 
scenario. At year 30, the baseline incidence of NG/CT is 17,393 cases per 100,000 
persons. This incidence rate falls to 15,007 cases per 100,000 persons under the 2x 
scenario, 13,000 cases per 100,000 persons under the 4x scenario, and 11,213 cases per 
100,000 persons under the 8x scenario. These represent decreases in incidence of 
13.72%, 25%, 35.53% over a 30-year period for the 2x, 4x, and 8x screen scenarios 
respectively. Each of the scenarios evaluating increased screening amongst high-risk 
MSM and the impact on NG/CT incidence show significantly reduced incidence relative 
to baseline levels. Furthermore, each of these decreases are significantly different from 
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each other. There is also a similar decline in NG/CT prevalence seen (Figure 4). As 
expected, the steepest declines in NG/CT prevalence are seen in the scenario with the 
highest screening probability. Unlike the trend seen in HIV prevalence, NG/CT 
prevalence seems to plateau in all scenarios after 40 years on continuous intervention. 
Regardless, significant declines are seen in all scenarios by year 20. 
 The number of tests for NG/CT under each scenario increased as expected. At 
baseline, the average number of tests for NG/CT per year was 3686. This number of tests 
given per year for NG/CT rose to an average of 7253 under the 2x scenario, 10,586 under 
the 4x scenario, and 14,266 under the 8x scenario. The increases in tests given 
corresponded to respective decreases in NG/CT incidence and prevalence.  
 
A General Increased Screening Program for HIV  
Impact on HIV Epidemic 
 
This screening strategy modeled the effect of increased general HIV screening in 
the MSM community, akin to a sustained “know your status” testing effort. The strategy 
modeled the general impact of increased HIV screening on HIV and NG/CT incidence by 
exploring the impact of 4 scenarios, which were the baseline (current scenario in 
Baltimore) and the following modulated probabilities; twice (2x) as likely, four times 
(4x), and 8 times (8x). The impact of each of baseline and the 3 increased screening 
scenarios on HIV incidence and total number of people screened per year are presented in 
Figs 5a and 5b. Fig 5a depicts the impacts of each scenario relative to baseline (Scenario 
11) on HIV incidence over time.  
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All increased screening scenarios illustrated reduced HIV incidence over time, 
with the magnitude of this decrease affected by each scenario’s increased screening 
probability. The graph depicts most differences in HIV incidence amongst all scenarios 
relative to baseline can be seen after 30 years of continuous intervention; with the 
scenarios modeling higher screening probability depicting faster reductions in incidence. 
The differences between HIV incidence at years 10, 20, 30, and 40 are significantly 
reduced from baseline for just the 4x screening scenario and the 8x screening scenario, 
assuming a significance level of p <0.05. The 2x screening scenario had a statistically 
significantly reduced incidence rate of HIV different from baseline when measured at 
years 30 and 40 (p <0.05), but not when measured at years 10 and 20.  The baseline 
incidence rate of HIV at year 10 was 1,433 cases per 100,000 persons. At year 10, the 2x 
screening scenario did not show any reduction in HIV incidence with 1433 cases per 
100,000 persons. However, at the same time point, the 4x and 8x screening scenarios 
respectively showed statistically significant decreases in HIV incidence, with the 4x 
screening scenario showing a reduction to 1,413 cases per 100,000 persons, and the 8x 
screening scenario showing a reduction to 1407 cases per 10,000 persons. At year 30, the 
baseline rate of HIV is still 1433 cases per 100,000 persons. All screening scenarios at 
year 30 show statistically significant reductions in HIV incidence; with the 2x scenario 
showing a reduction to 1420 cases per 10,000 persons, the 4x scenario showing a 
reduction to 1387 cases per 100,000 persons, and the 8x scenario showing a reduction to 
1360 cases per 100,000 persons. These represent decreases in HIV incidence of 0.9%, 
3.2%, and 5.1% over a 30-year period for the 2x, 4x, and 8x screening scenarios 
respectively.  To test for difference between each of the screening scenarios, one-way 
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ANOVA’s were also run to determine differences in the mean incidence rate at year 10. 
The tests showed at that this time point, the HIV incidence rate is significantly different 
between all increased screening scenarios. Fig 5b depicts the impact of each scenario 
relative to baseline on total persons screened for HIV. Each scenario shows a similar 
pattern of an increase in tests given for HIV initially before leveling off. However, this 
yearly amount HIV tests givens varies noticeably between of the three scenarios, with the 
8x scenario depicting the largest increase in HIV tests given relative to the other 
scenarios. In this set of scenarios, we also observe slight fluctuating trends in HIV 
prevalence, with no clear evidence of a decline in HIV prevalence within 30 years after 
starting the intervention (Fig 6). 
To achieve these decreases in HIV incidence and prevalence, more HIV tests 
were administered. The average number of HIV tests given per year at baseline was 6,753 
MSM. This increased to 9,368 HIV tests given per year under the 2x scenario, 14,596 
under the 4x scenario, and 25051 under the 8x scenario. The increase in HIV tests given 
corresponded to larger declines in HIV incidence and prevalence in each scenario. 
Impact on the NG/CT Epidemic 
The impact of increased general HIV screening on NG/CT incidence is depicted 
in figure 7. Observed declines in incidence are only seen after 25 years of continuous 
intervention, and all scenarios here exhibit the pattern of NG/CT incidence stabilizing 
around year 40. There appears to be differences in NG/CT incidence by scenario. To 
determine if any of these observed differences were statistically significant, one-way 
ANOVA tests were performed between each scenario at years 25, 30, 40 and 50 and 
baseline. The 2x, 4x, and 8x, screening scenarios only showed a significantly (p <0.01) 
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reduced incidence rate different from baseline measured at years 30 and 40.  To test for 
differences between each scenario, one way- ANOVA tests were also conducted. These 
were compared at Years 10, 20, 30, and 40. These results illustrate that there is some 
fluctuation in NG/CT incidence between the increased screening scenarios; but after year 
30 significant differences (p<0.05) in NG/CT incidence rates become more apparent, and 
the trend continues for the rest of the scenario. This is seen in figure 8. At year 30, the 
baseline rate of NG/CT is 17367 cases per 100,000 persons. All screening scenarios show 
significantly reduced incidence of NG/CT; with the 2x scenario showing a reduction to 
17,007 cases cases per 100,000 persons, the 4x scenario showing a reduction to 16,613 
cases per 10,000 persons, and the 8x scenario showing a reduction to 16,400 cases per 
cases per 10,000 persons. These represent decreases in NG/CT incidence over a 30-year 
period of 2.07%, 4.24%, and 5.56% respectively. 
Interestingly the pattern of each scenario’s impact on NG/CT prevalence almost 
exactly mirrors that of the pattern of NG/CT incidence (Fig 8). We again see NG/CT 
prevalence diverge slightly in the first few years before beginning to decline for good 
around year 20 for all scenarios. The magnitude in the decline again mirrors the increase 
in screening probability by scenario. The declines in prevalence are significant for all 
scenarios starting at year 30, but this decline plateaus in year 40, just 10 years later. This 
reflected in both the trend seen in fig 8, and in the close test statistical year 30 and 40 for 
each scenario. 
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Increased screening for NG/CT Amongst HIV-Infected MSM 
Impact on the HIV Epidemic  
To model the impact of increasing the proportion of HIV-infected MSM screened 
for NG/CT, a set of scenarios were run that modeled this proportion relative to baseline 
(0.4) The scenario proportions for 0.6, 0.8 and 1 (the CDC recommended screening 
guideline). Each of these scenarios assume that persons testing positive will be treated for 
NG/CT and rendered no longer infectious, also impacting the HIV/NG/CT co-infection 
parameter. Additionally, all scenarios assume that there is no increase in HIV testing 
beyond baseline. The impact of increasing the proportion of HIV infected MSM screened 
on HIV incidence is shown in Figure 9. 
There does not appear to be any impact on HIV incidence by increasing the proportion of 
HIV infected MSM screened. The baseline (0.4) and the other 3 scenarios (screening 
proportions 0.6, 0.8, and 1) do not appear to result in any significant differences in 
incidence over time, as the incidence lines overlap throughout the whole 50-year model 
run period. ANOVA tests conducted to test differences in incidence rate at different time 
points confirmed this observation. Increasing the proportion of HIV of infected MSM 
from NG/CT also does not appear to impact HIV prevalence (Fig 10). The range of 
prevalence in the Baltimore MSM population ranges from from 3210 cases to 3250 cases, 
a range of only 40 cases. One-way ANOVA tests confirm the lack of difference in 
prevalence between scenario. 
Impact on the NG/CT Epidemic 
 
There does appear to be a difference in NG/CT incidence over time as seen in Fig 
11a. These differences appear slight, relative to the other two scenario groups. 
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Furthermore, the differences in NG/CT incidence become observable at a later time point 
relative to the other screening strategies, with these differences becoming noticeable 
around year 40. Similar to the trend seen in NG/CT incidence, there appears to little 
impact on NG/CT prevalence as well (fig 12). One-way ANOVA tests confirm that 
significant declines in prevalence only start to be see at year 40 and level off (p < 0.001). 
Tests were conducted until year 50, to in order to capture the full trend of N/CT 
prevalence. 
Comparing HIV Screening Strategies  
 
While both the targeted screening and general HIV screening strategies resulted in 
decreases incidence in both diseases, the magnitude of the decrease and the number HIV 
tests given to achieve the decrease differed greatly between strategies (tables 2 and 3). 
The least aggressive screening scenario (the 2x scenario) for targeting high-risk MSM 
resulted in a roughly 5% decrease in HIV incidence, and achieved this by an average of 
10,116 HIV tests given per year. The scenario in the general HIV screening strategy that 
most closely realizes these decreases in HIV incidence is the 8x screening scenario (a 
5.1% reduction), which was achieved giving an average of 25,051 HIV tests per year. In 
order to achieve the same decrease in HIV incidence, the general HIV screening model 
had to give nearly 15,000 more HIV tests compared to the 2x increased screening in the 
high-risk MSM screening strategy, 148% more MSM relative to the 2x scenario. In other 
terms for the 2x targeted screening scenario, just giving 2,175 tests annually led to a 1% 
decrease in HIV incidence over a 30-year period, compared to under the 8x general 
screening scenario where 4,912 tests had to be given annually to achieve same result.  
Therefore, despite giving more HIV tests, the most intensive general screening strategy 
 29 
barely outperformed the least aggressive high-risk MSM screening strategy. To further 
accentuate this disparity in HIV tests given versus reduction in HIV incidence, the 8x 
(most aggressive) screening strategy targeting high-risk MSM resulted in a 12.5% 
reduction in HIV incidence, and achieved this by giving 16,733 HIV tests per year. Thus 
despite giving 8,313 HIV tests less than the comparable general HIV screening strategy, 
the reduction in incidence was more than doubled. Of further note, the 8x targeted 
screening scenario achieved a 1% reduction in HIV incidence more efficiently than the 
2x targeted screening scenario, with just 1,338 tests given annually compared with 2,175 




  Of the three screening strategies tested, targeting high-risk MSM, improving 
general HIV screening, and increasing the proportion of HIV-infected MSM screened for 
NG/CT; only the scenarios that increased targeted high-risk MSM and general HIV 
screening strategies showed consistent reductions in HIV or NG/CT incidence. The 
results here illustrate that targeting this specific MSM subpopulation can result in a 
profound reduction in the HIV and NG/CT epidemics in Baltimore while requiring 
substantially less HIV and NG/CT testing.  While high-risk young MSM can be a more 
difficult population to reach for HIV testing87,88, it may be a better use of HIV control 
resources and effort to target them for HIV and NGCT testing; as evidenced by the 
reductions in tests given to achieve a 1% reduction in HIV incidence in the MSM 
population as a whole. For HIV control programs faced with limited resources and 
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budgets, using less HIV tests to target high-risk MSM can produce far greater reductions 
in HIV incidence than a general screening program, allowing for gains in program 
efficiency while using less resources, assuming the trade-off for reaching this population 
is lower than the number of tests saved. Furthermore, the substantial reduction in 
incidence in the overall population being brought about by targeting a subset of the 
population suggests that the high-risk subpopulation, which is mostly comprised of young 
MSM (YMSM) has a higher burden of HIV relative to the general MSM population, with 
HIV transmission and infection being partially localized within this group. Conversely, 
there could be a higher number of persons in this population who are unaware of their 
HIV infection and due to a higher propensity of engaging in casual partnerships, are more 
likely to transmit the virus. Still, the difference in the impact on HIV incidence in each 
screening scenarios suggests retrospectively, at least in Baltimore, the HIV epidemic is 
concentrated in the YMSM high-risk population. 
    While the differences in NG/CT incidence decline were expected, as the general 
HIV screening strategy did not test for NG/CT and the screening strategy targeting high-
risk MSM did, the difference in reduction of NG/CT was noticeable. The 8x screening 
scenario for the general HIV screening strategy resulted in a 5.56% decrease in NG/CT 
incidence after 30 years and achieved this by giving 25,051 NG/CT tests per year; 
whereas the 2x screening scenario targeting high-risk MSM resulted in a 13.72% 
reduction in NG/CT incidence after 30 years by just giving 10,586 NG/CT tests per year. 
While certainly directly testing for NG/CT and linking those persons to treatment under 
the high-risk MSM screening strategy explains the disparity in incidence decline, the 
difference in number of persons screened versus decline in incidence is striking in its 
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magnitude. That the 4x and 8x high-risk screening scenario achieved 25% and 35% 
reductions in NG/CT incidence by giving fewer NG/CT tests per year is notable given the 
high incidence rate of NG/CT in the general MSM population. This could be due to a 
higher burden of NG/CT in the high-risk subpopulation, but clearly targeting them for 
increased screening and treatment can result in a marked reduction in NG/CT incidence 
amongst the MSM population in Baltimore. While is this scenario there was not the 
perfect comparison to a general NG/CT screening strategy, the magnitude of the decrease 
in NG/CT suggests that, as noted with HIV above, the NG/CT epidemic amongst MSM 
in Baltimore is concentrated in this subpopulation of YMSM. Additionally, it is 
encouraging that the general HIV screening strategy did in fact reduce NG/CT incidence 
even though NG/CT was not directly targeted by this intervention, as it supports the idea 
that co-epidemics of NG/CT help propagate each other. Thus, improving screening of 
HIV and subsequently linking infected persons to care can have a radiating impact on 
other STI co-epidemics, resulting in incidence reduction of NG/CT, and possibly other 
STIs; and therefore could be considered as part of an integrated STI (HIV and others) 
control strategy. Further research could shed light on the impacts of other STI’s, such as 
syphilis, and the impacts of improved screening and treatment on HIV and NG/CT 
epidemics.  
 Increasing the proportion of HIV-infected MSM screened for NG/CT had no 
impact on HIV incidence and prevalence, and little impact on NG/CT incidence and 
prevalence. This could be due to the fact that the HIV-Infected MSM population is 
already a small subset of the overall MSM population, and amongst that group, those also 
infected and who will become infected with NG/CT is an even smaller group. Therefore, 
 32 
since this strategy is targeting only a small segment of the population, it had little impact 
on either epidemic Future research could focus on the impact of general NG/CT 
screening and its impact on the NG/CT and HIV incidence, and comparing that to the 
targeted screening strategy.  
   There is a dearth of agent-based HIV modelling studies, but the conclusions here 
agree with the existing body of literature on modelling HIV screening. Brookmeyer et al 
used an agent based model to study the percentage of cases of HIV prevented using a 
various components and combinations of HIV prevention strategies.88 In the scenario 
evaluating general HIV testing alone, where testing was increased 150%, they found that 
this prevented 4.9% of HIV cases.88 This is akin to the strategy in our model evaluating 
general increased HIV screening, whereby the most intensive scenario has a similar 5% 
reduction in HIV incidence. Similarly, a compartmental model developed by Sorensen et 
al found that doubling the annual testing rate (akin to the 2x screening scenario for 
general HIV screening) in New York City could potentially reduce the prevalence of HIV 
by 5% from projected levels over a 20 year period.89 While this is a notable improvement 
over the reduction in prevalence in the 2x general (0.9%  reduction) HIV screening 
scenario in our model, the different methodology in this modelling approach (in that 
agent-based models arguably better capture stochastic dynamics of epidemics than 
compartment based models) and the different geographic settings could explain the 
difference. No specific literature regarding modelling targeted high-risk MSM screening 
was found. 
   In our model, high-risk MSM are modeled as a function of each agent’s age and 
sexual activity level; with high-risk MSM being those who are younger and more 
 33 
sexually active. High-risk MSM are often defined in the literature by their age and risk 
behaviors such as unprotected anal intercourse and multiple sexual partners.90 Prior 
studies on high-risk and young MSM (YMSM) suggest that the level of screening in this 
population is slightly higher than that of the general population, but not as high as it 
should be given the increased risk of HIV acquisition.91 YMSM are more likely to be 
unaware of their HIV infection, and this in combination with the higher likelihood of 
having more sexual partners, suggests that YMSM can have a high probability of 
transmitting HIV to a large number of persons in the MSM community.91 Young MSM 
are also more likely to have multiple casual sexual partnerships92,93, and have unprotected 
sex93, and meet partners over the internet.93 All of these factors in conjunction form a risk 
environment that favors the increased transmission of HIV and other STIs relative the 
general population and general MSM population.90 Therefore, not surprisingly given the 
increased risk and transmission in this population , increasing HIV testing and NG/CT 
testing and treatment in this population can greatly decrease the incidence of these two 
diseases. 
  In tandem, the results illustrate that targeted screening to high-risk MSM has the 
most impact amongst these three scenarios. Given that majority of high-risk MSM in 
model are younger men, and the high HIV prevalence and risk of acquisition has been 
documented 92, targeted them is not entirely unsurprising. As such, the model results 
suggest it may be more efficient and impactful to target high-risk MSM for increased 
HIV and NG/CT screening, rather than pursuing a general HIV testing campaign in the 
MSM community. Not only are greater reductions in HIV and NG/CT incidence seen, but 
these results are achieved by giving thousands less HIV and NG/CT tests. Since this 
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result is achieved by giving less tests, this in turn could potentially lessen person-hours 
and cost to HIV and NG/CT control programs. Thus, the combination of improved 
outcomes in decreased incidence and achieving this by screening less MSM, suggest that 
targeting high-risk MSM is the more efficacious screening strategy. 
While the model did approximate the impact of increased screening strategies, the 
actual process of increasing persons screened was not studied. Thus, while the model 
shows the benefits of increasing screening, the potential changes to achieve this could be 
difficult to put into practice.  There is a plethora of literature on barriers to improving 
HIV and STI screening, ranging from racial and stigma related barriers, to cost and ease-
of-access barriers.94 Further complicating matters is that model’s suggestion that 
targeting high-risk MSM for increased screening is most effectives involves a difficult 
and hard to reach population of the MSM community. Not only could achieving 
increased targeted screening be difficult, but also potentially more expensive, as the cost 
to reach and test this population is greater than the cost of pursuing a general HIV testing 
strategy in the MSM community. However, the model suggests that less MSM need to be 
screened to achieve greater reductions in incidence, and thus money saved by testing less 
persons could mitigate the potential increased cost of seeking out this population. This 
cost-benefit and feasibility analysis should be done to determine the efficacy of pursuing 
this targeted strategy in practice. 
  As with all modeling studies, one key limitation is the model necessarily 
oversimplifies very complex disease dynamics While our model is parameterized to 
Baltimore City data, it is unlikely that the true magnitude of what transpired in the model 
will play out exactly in a real-world setting. As such the true impact of these screening 
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scenarios may be either greater or lesser than the impact seen in the model. While there 
may be substantial uncertainty regarding the absolute levels of the results here, there may 
be less uncertainty regarding relative measures (such as the relative impact of screening 
targeted at high-risk populations versus the entire MSM community more generally). 
Confounding by race was not accounted or evaluated for in this study. Baltimore is a 
diverse city, and there are large populations of black and Caucasian MSM. There could 
be different rates and impacts of each of the screening strategies if we stratify by race due 
to differing likelihoods of accessing care by race. However, the model does attempt to 
account for this with a parameter for this racial disparity in HIV care access; and thus the 
impact of racial differences in HIV care access and screening should be accounted for 
and have minimal bias. 
    In conclusion, the study suggests that the most effective screening scenario is one 
that targets high-risk MSM. The simulation suggests that, depending on extent of 
screening probability increase, could decrease the incidence of HIV alone by 5-14%, and 
NG/CT by 5-35%. While the true effect is likely different in the real world, and could 
face other potential pitfalls given that it targets a hard to reach population, the impact as 
demonstrated by the model is clear; targeting high-risk MSM for HIV and NG/CT 
screening can achieve significantly reductions in incidence of these diseases while 
simultaneously giving less tests. As such, increased attention should be paid towards 
High-Risk MSM populations going forward in order to produce a larger impact on the 
HIV and NG/CT epidemics. Thus, this targeted screening strategy, in tandem with other 
HIV and STI control methods, could help control and eventually help end the HIV and 
NG/CT epidemic in Baltimore 
 36 
Tables and Figures 
 
Table 1: List of Parameters 
  
Fixed Parameters Value Reference 
Partnerships    
Age Mixing: Absolute difference in square root of 
ages (ADSR) 
- Stable partnerships 





Race mixing: Likelihood of mixing with a partner 
of the same race 
- Black-Black 






Likelihood of condom use 
- Stable partnerships 
- Casual partnerships 
[Never, Partially, Always] 
[0.45, 0.55, 0.00]  
[0.47, 0.12, 0.41] 
1 
Sexual position preference: 
- Insertive only 







GC    
Proportion of cases symptomatic  











Duration of infection in the absence of treatment  Uniform (3-12) months 6–20 
Duration of treatment 2 weeks 6,21,22 
Regular GC screening intervals for HIV+ MSM: 
- All MSM on ART: 




 6 months 
23 
Likelihood of compliance with guideline 
(presenting for scheduled appointment) 
 
35% 24–29 
Efficacy of condoms to prevent GC transmission 70% 6,30,31 
Increase in HIV transmissibility (from urethral or 
rectal infection) 
Uniform [1.5-2] fold  32–36 
Increase in HIV susceptibility (from urethral or 
rectal infection) 
Uniform [1-2.5] fold  
 
5,6,36,37  
HIV    
Disease state duration   
   Acute infection (CD4 >500 cells/µL) [6, 9] weeks 38–40 
   Chronic infection (CD4 200-499 cells/µL) [8, 10] years 38,41 
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A: Mortality rate in late infection is defined as 1/(duration in the late infection disease state. 
 B Infectiousness assumed equal to that of the chronic state 
D If a person start ART during the chronic state, they’ll mortality level will be immediately reduced according to this 
cofactor. However, if he start ART in the later state, he’ll be subjected to the late state mortality level for a period of 
time before reverting back to the chronic state. This duration is estimate as the time spent in the late state up to one 
year. once in the chronic state, the person will be subjected to the baseline mortality level of 5 per 1000 p/y times the 
ART cofactor. 
   Late infection (CD4 <200 cells/µL) 1 [1, 3] years 38,39,41 
Time from ART initiation to full viral suppression [4-24] weeks 42 
Maximum duration of time to stay in late state 
after ART initiation before reverting to chronic 
state 
52 weeks  
Time from ART discontinuation to pre-ART CD4 
nadir2 
ART treatment duration up to 
one yearb 
43–46 
Mortality rate 3 
   Acute and chronic, no ART 
   Late, no ART 
   Reduction in mortality due to ART3 
 
5 per 1000 person years 
1/duration of late infection 




Average viral load (log10 copies/mL) 
  Acute, no ART 
  Chronic, no ART 
  Late, no ART 
  On ART, partially suppressed 









Efficacy of condoms to prevent HIV transmission 80% 50,51 
Infectiousness for HIV per sexual contact 2.45 (log(VL)-4.5) 38 
Annual probability of engagement in HIV care .3c 52–54 
Weekly probability of ART discontinuation 0.015d 55 
Minimum gap in care after ART discontinuation 26 weeks 56 
Parameters calibrated to population-level 
surveillance data 
  
Site specific probability of NG/CT transmission  
per act 
-  Urethral 
- Rectal 






Weekly probability of symptomatic NG/CT testing 
-  Urethral 
- Rectal 






Background rate of screening MSM for HIV and 
NG/CT 
0.014  
Proportion of MSM screened for NG/CT annually  .40  
Probability that NG/CT screening occurs only at 
urethral site 
0.93  
Weekly probability of: 
- Screening for HIV only  










- Starting ART (if linked to care) 




Relative likelihood of accessing HIV care among 
Black MSM 
0.5  
Table 2: Contrasting Screening Strategies Results on HIV Rates 
 Targeted Screening for High-risk MSM General HIV Screening 
 2x 4x 8x 2x 4x 8x 
Avg. number 
of HIV tests 
given per year 











4.65% 9.23% 12.50% 0.90% 3.20% 5.10% 
Table 3: Contrasting Screening Strategies Results on NG/CT Rates 
 Targeted Screening for High-risk MSM General HIV Screening 
 2x 4x 8x 2x 4x 8x 
Avg. number of 
NG/CT tests per 
year 
7,253 10,586 14,266 NA NA NA 
Incidence  Rate 
per 100,000 
persons at year 30 











Figures 1a and 1b: HIV Incidence and HIV Tests Given Annually Over a 50-year 
period for the High-Risk MSM Screening Strategy  
Figs 1a and 1b: 1a presents HIV incidence per 15,000 MSM by scenario under the targeted screening of 
high-risk MSM strategy. 1b presents the total number of HIV tests given per year over a 50 year period 
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Fig 2: Presents HIV prevalence per 15,000 persons by scenario for each year 
under the targeted screening of high-risk MSM strategy. 
. 





    
Figs 3a and 3b: 3a presents NG/CT incidence per 15,000 MSM by scenario under the targeted 
screening of high-risk MSM strategy. 3b presents the total number of NG/CT tests given each year 
by scenario under the same strategy.  
Figure 3: NG/CT Incidence and NG/CT Tests Given Annually Over a 50-year period for the 









































Fig 4: Presents NG/CT prevalence per 15,000 persons by 
scenario for each year under the targeted screening of high-
risk MSM strategy. 
Figure 4: NG/CT Prevalence Over a 50-year period for the High-Risk MSM Screening 
Strategy  
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   Figures 5a and 5b: HIV Incidence and HIV Tests Given Annually Over a 50-year 
period for the General HIV Screening Strategy  
Figs 5a and 5b: 5a presents HIV incidence per 15,000 MSM, by scenario under the increased general 
HIV screening strategy.  5b presents the total number of HIV tests given each year by scenario under 






































Fig 6: HIV prevalence per 15,000 persons by scenario for each 
year under the increased general HIV screening strategy. 
Figure 6: HIV Prevalence Given Annually Over a 50-year period for the General HIV 
Screening Strategy  
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Fig. 7 presents NG/CT incidence per 15,000 MSM for each year by scenario under the 
increased general HIV screening strategy 
Fig 8: Presents NG/CT prevalence per 15,000 persons by scenario for 
each year under the increased general HIV screening strategy. 
Figure 7: NG/CT Incidence Over a 50-year period for General HIV Screening Strategy  















Fig 9 presents HIV incidence under the increased NG/CT screening strategy for 15,000 
MSM for each year by each scenario. 
Fig 10: Presents HIV prevalence under the increased NG/CT screening 
strategy per 15,000 persons by scenario for each year. 
Figure 9: HIV Incidence Over a 50-year period for the Increasing NG/CT Screening Amongst 
HIV Infected MSM Strategy  
Figure 10: HIV Incidence Over a 50-year period for the Increasing NG/CT Screening 










Figures 11a and 11B:NG/CT Incidence and Number of MG/CT Tests Given Annually 
Over a 50-year period for the Increasing NG/CT Screening Amongst HIV Infected 
MSM Strategy  
Figs 11a and 11b: 1a presents NG/CT incidence per 15,000 MSM for each year under the increased 
NG/CT screening strategy.1b presents the total number of MSM screened each year for NG/CT under 































Fig 12: Presents NG/CT prevalence per 15,000 persons by scenario for 
each year under the increased NG/CT screening strategy 
Figure 12: NG/CT Prevalence Over a 50-year period for the Increasing NG/CT Screening 




1.  Maryland Department of Health and Mental Hygiene. BESURE Study 2004-2014: Baltimore site 
of National HIV Behavioral Surveillance (NHBS). 
2.  Kent CK, Chaw JK, Wong W, et al. Prevalence of Rectal, Urethral, and Pharyngeal Chlamydia and 
Gonorrhea Detected in 2 Clinical Settings among Men Who Have Sex with Men: San Francisco, 
California, 2003. Clin Infect Dis. 2005;41(1):67-74. doi:10.1086/430704. 
3.  Lister N, Smith A, Tabrizi S, Hayes P. Screening for Neisseria gonorrhoeae and Chlamydia 
trachomatis in men who have sex with men at male-only saunas. Sex Transm. 2003. 
4.  Sherrard J, Barlow D. Gonorrhoea in men: clinical and diagnostic aspects. Genitourin Med. 
1996;72(6):422-426. http://www.ncbi.nlm.nih.gov/pubmed/9038638. Accessed January 18, 2017. 
5.  Morris SR, Klausner JD, Buchbinder SP, et al. Prevalence and incidence of pharyngeal gonorrhea 
in a longitudinal sample of men who have sex with men: the EXPLORE study. Clin Infect Dis. 
2006;43(10):1284-1289. doi:10.1086/508460. 
6.  Beck EC, Birkett M, Armbruster B, Mustanski B. A Data-Driven Simulation of HIV Spread 
Among Young Men Who Have Sex With Men: Role of Age and Race Mixing and STIs. J Acquir 
Immune Defic Syndr. 2015;70(2):186-194. doi:10.1097/QAI.0000000000000733. 
7.  Kretzschmar M, Duynhoven Y van. Modeling prevention strategies for gonorrhea and chlamydia 
using stochastic network simulations. Am J. 1996. 
8.  Korenromp EL, Sudaryo MK, de Vlas SJ, et al. What proportion of episodes of gonorrhoea and 
chlamydia becomes symptomatic? Int J STD AIDS. 2002;13(2):91-101. 
http://www.ncbi.nlm.nih.gov/pubmed/11839163. Accessed January 18, 2017. 
9.  Althaus CL, Heijne JCM, Roellin A, Low N. Transmission dynamics of Chlamydia trachomatis 
affect the impact of screening programmes. Epidemics. 2010;2(3):123-131. 
doi:10.1016/j.epidem.2010.04.002. 
10.  Price MJ, Ades AE, Angelis D De, et al. Mixture-of-exponentials models to explain heterogeneity 
in studies of the duration of Chlamydia trachomatis infection. Stat Med. 2013;32(9):1547-1560. 
doi:10.1002/sim.5603. 
11.  Turner KM, Adams EJ, Gay N, Ghani AC, Mercer C, Edmunds WJ. Developing a realistic sexual 
network model of chlamydia transmission in Britain. Theor Biol Med Model. 2006;3:3. 
doi:10.1186/1742-4682-3-3. 
12.  Chesson HW, Pinkerton SD. Sexually transmitted diseases and the increased risk for HIV 
transmission: implications for cost-effectiveness analyses of sexually transmitted disease 
prevention interventions. J Acquir Immune Defic Syndr. 2000;24(1):48-56. 
http://www.ncbi.nlm.nih.gov/pubmed/10877495. Accessed January 18, 2017. 
13.  Chesson HW, Bernstein KT, Gift TL, Marcus JL, Pipkin S, Kent CK. The cost-effectiveness of 
screening men who have sex with men for rectal chlamydial and gonococcal infection to prevent 
HIV Infection. Sex Transm Dis. 2013;40(5):366-371. doi:10.1097/OLQ.0b013e318284e544. 
14.  Tuite A, Jayaraman G, Allen V. Estimation of the burden of disease and costs of genital Chlamydia 
trachomatis infection in Canada. Sex Transm. 2012. 
15.  Vries R De, Bergen J Van. Systematic screening for Chlamydia trachomatis: estimating cost‐
effectiveness using dynamic modeling and Dutch data. Value in. 2006. 
16.  Adams EJ, Turner KME, Edmunds WJ. The cost effectiveness of opportunistic chlamydia 
screening in England. Sex Transm Infect. 2007;83(4):267-74-5. doi:10.1136/sti.2006.024364. 
17.  Andersen B, Gundgaard J, Kretzschmar M. Prediction of costs, effectiveness, and disease control of 
a population-based program using home sampling for diagnosis of urogenital Chlamydia 
trachomatis. Sex Transm. 2006. 
18.  Gillespie P, O’Neill C, Adams E, Turner K. The cost and cost-effectiveness of opportunistic 
screening for Chlamydia trachomatis in Ireland. Sex Transm. 2012. 
19.  Roberts T, Robinson S, Barton P, Bryan S. Cost effectiveness of home based population screening 
for Chlamydia trachomatis in the UK: economic evaluation of chlamydia screening studies (ClaSS) 
project. Bmj. 2007. 
20.  WELTE R, KRETZSCHMAR M, LEIDL R. Cost-effectiveness of screening programs for 
Chlamydia trachomatis: a population-based dynamic approach. Sex Transm. 2000. 
 50 
21.  Vriend HJ, Lugnér AK, Xiridou M, et al. Sexually transmitted infections screening at HIV 
treatment centers for MSM can be cost-effective. AIDS. 2013;27(14):2281-2290. 
doi:10.1097/QAD.0b013e32836281ee. 
22.  Chen MI, Ghani AC, Edmunds WJ. A metapopulation modelling framework for gonorrhoea and 
other sexually transmitted infections in heterosexual populations. J R Soc Interface. 
2009;6(38):775-791. doi:10.1098/rsif.2008.0394. 
23.  Sexually transmitted diseases treatment guidelines, 2006. MMWR recomm. 2006. 
24.  Berry SA. Gonorrhoea and chlamydia screening in HIV clinics: time for new tools and targets. Sex 
Transm Infect. 2014;90(8):574-575. doi:10.1136/sextrans-2014-051700. 
25.  Berry SA, Ghanem KG, Page KR, et al. Increased gonorrhoea and chlamydia testing did not 
increase case detection in an HIV clinical cohort 1999-2007. Sex Transm Infect. 2011;87(6):469-
475. doi:10.1136/sextrans-2011-050051. 
26.  Hutchinson J, Goold P, Wilson H, Jones K, Estcourt C. Sexual health care of HIV-positive patients: 
an audit of a local service. Int J STD AIDS. 2003;14(7):493-496. 
doi:10.1258/095646203322025821. 
27.  Hamlyn E, Barrett S, Kelsey J, Lockyer S, Welz T, Poulton M. Improvement in screening for 
sexually transmitted infections in HIV-positive patients following implementation of a nurse-led 
clinic. Int J STD AIDS. 2007;18(6):424-426. doi:10.1258/095646207781024720. 
28.  Hoover KW, Butler M, Workowski K, et al. STD screening of HIV-infected MSM in HIV clinics. 
Sex Transm Dis. 2010;37(12):771-776. doi:10.1097/OLQ.0b013e3181e50058. 
29.  Teague R, Mijch A, Fairley CK, et al. Testing rates for sexually transmitted infections among HIV-
infected men who have sex with men attending two different HIV services. Int J STD AIDS. 
2008;19(3):200-202. doi:10.1258/ijsa.2007.007131. 
30.  Joesoef MR, Linnan M, Barakbah Y, Idajadi  a, Kambodji  a, Schulz K. Patterns of sexually 
transmitted diseases in female sex workers in Surabaya, Indonesia. Int J STD AIDS. 1997;8(9):576-
580. doi:10.1258/0956462971920811. 
31.  Darrow WW. Condom Use and Use-Effectiveness in High-Risk Populations. SexTransmDis. 
1989;16(3):157-160. 
32.  Cohen M. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet. 
1998. 
33.  Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: 
the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex 
Transm Infect. 1999;75(1):3-17. doi:10.1136/sti.75.1.3. 
34.  Winter AJ, Taylor S, Workman J, et al. Asymptomatic urethritis and detection of HIV-1 RNA in 
seminal plasma. Sex Transm Infect. 1999;75(4):261-263. 
http://www.ncbi.nlm.nih.gov/pubmed/10615314. Accessed January 18, 2017. 
35.  Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after 
treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet. 
1997;349(9069):1868-1873. doi:10.1016/S0140-6736(97)02190-9. 
36.  R??TTINGEN J-A, WILLIAM CAMERON D, GARNETT GP. A Systematic Review of the 
Epidemiologic Interactions Between Classic Sexually Transmitted Diseases and HIV. Sex Transm 
Dis. 2001;28(10):579-597. doi:10.1097/00007435-200110000-00005. 
37.  Jin F, Prestage GP, Imrie J, et al. Anal Sexually Transmitted Infections and Risk of HIV Infection 
in Homosexual Men. JAIDS J Acquir Immune Defic Syndr. 2010;53(1):144-149. 
doi:10.1097/QAI.0b013e3181b48f33. 
38.  Beyrer C, Baral SD, van Griensven F, et al. Global epidemiology of HIV infection in men who 
have sex with men. Lancet (London, England). 2012;380(9839):367-377. doi:10.1016/S0140-
6736(12)60821-6. 
39.  Baggaley RF, Ferguson NM, Garnett GP. The epidemiological impact of antiretroviral use 
predicted by mathematical models: a review. Emerg Themes Epidemiol. 2005;2(1):9. 
doi:10.1186/1742-7622-2-9. 
40.  Salomon JA, Hogan DR, Stover J, et al. Integrating HIV prevention and treatment: from slogans to 
impact. Lange J, ed. PLoS Med. 2005;2(1):e16. doi:10.1371/journal.pmed.0020016. 
41.  Alam SJ, Meyer R, Norling E. A model for HIV spread in a South African village. Multi-Agent-
Based Simul IX. 2009:33-45. 
 51 
42.  Clotet B, Feinberg J, Lunzen J van, Khuong-Josses M. Once-daily dolutegravir versus darunavir 
plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results 
from the randomised. Lancet. 2014. 
43.  Wit FW, Blanckenberg DH, Brinkman K, et al. Safety of long-term interruption of successful 
antiretroviral therapy: the ATHENA cohort study. AIDS. 2005;19(3):345-348. 
http://www.ncbi.nlm.nih.gov/pubmed/15718848. Accessed January 18, 2017. 
44.  Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged 
discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. 
2004;18:439-446. doi:10.1097/01.aids.0000111418.91384.19. 
45.  Ortiz GM, Wellons M, Brancato J, et al. Structured antiretroviral treatment interruptions in 
chronically HIV-1-infected subjects. Proc Natl Acad Sci. 2001;98(23):3288-13293. 
46.  El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral 
treatment. New Engl J Med. 2006;355(22):2283-2296. 
47.  The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV 
infection. N Engl J Med. 2015;373:795-807. 
48.  Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy 
for HIV on survival. N Engl J Med. 2009;360(18):1815-1826. 
49.  Palella FJ, Delaney KM, Moorman AC, et al. Declining Morbidity and Mortality among Patients 
with Advanced Human Immunodeficiency Virus Infection. N Engl J Med. 1998;338(13):853-860. 
doi:10.1056/NEJM199803263381301. 
50.  Sc W, Davis-Beaty. Condom effectiveness in reducing heterosexual HIV transmission (Review). 
51.  Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted 
infections. Bull World Health Organ. 2004;82(6):454-461. doi:10.1590/S0042-
96862004000600012. 
52.  Hill T, Bansi L, Sabin C, Phillips A, Dunn D. Data linkage reduces loss to follow-up in an 
observational HIV cohort study. J Clin. 2010. 
53.  Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A. Loss to follow‐up in an international, 
multicentre observational study. HIV. 2008. 
54.  Ndiaye B, Ould-Kaci K, Salleron J, Bataille P. Characteristics of and outcomes in HIV-infected 
patients who return to care after loss to follow-up. Aids. 2009. 
55.  Mills E, Nachega J, Buchan I, Orbinski J. Adherence to antiretroviral therapy in sub-Saharan Africa 
and North America: a meta-analysis. Jama. 2006. 
56.  Rana AI, Liu T, Gillani FS, et al. Multiple gaps in care common among newly diagnosed HIV 
patients. AIDS Care. 2015;27(6):679-687. doi:10.1080/09540121.2015.1005002. 
57.  BCHD. Jurisdictional Plan for HIV Prevention in Baltimore City. Baltimore City; 2012. 
58.  CDC. STD Screening Recommendations - 2015 STD Treatment Guidelines. The Centers for 
Disease Control. https://www.cdc.gov/std/tg2015/screening-recommendations.htm. Published 
2015. Accessed January 17, 2017. 
59.  Weir SS, Feldblum PJ, Roddy RE, Zekeng L. Gonorrhea as a risk factor for HIV acquisition. AIDS. 
1994;8(11):1605-1608. http://www.ncbi.nlm.nih.gov/pubmed/7848598. Accessed January 19, 
2017. 
60.  Ward H, Rönn M. Contribution of sexually transmitted infections to the sexual transmission of 
HIV. Curr Opin HIV AIDS. 2010;5(4):305-310. doi:10.1097/COH.0b013e32833a8844. 
61.  Scott KC, Philip S, Ahrens K, Kent CK, Klausner JD. High prevalence of gonococcal and 
chlamydial infection in men who have sex with men with newly diagnosed HIV infection: an 
opportunity for same-day presumptive treatment. J Acquir Immune Defic Syndr. 2008;48(1):109-
112. doi:10.1097/QAI.0b013e318165dc0b. 
62.  Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: 
a systematic review and meta-analysis. Sex Transm Dis. 2008;35(11):946-959. 
doi:10.1097/OLQ.0b013e3181812d15. 
63.  Williams P, Ekundayo O. Study of distribution and factors affecting syphilis epidemic among 
inner-city minorities of Baltimore. 




65.  Jinno S, Anker B, Kaur P, Bristow CC, Klausner JD. Predictors of serological failure after 
treatment in HIV-infected patients with early syphilis in the emerging Era of universal 
antiretroviral therapy use. http://www.biomedcentral.com/1471-2334/13/605. 
66.  Cohen MS et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 
2016;375.9:830-839. 
67.  National HIV/AIDS Strategy for the United States: Updated to 2020. Washington DC; 2015. 
68.  Ulett KB, Willig JH, Lin H-Y, et al. The therapeutic implications of timely linkage and early 
retention in HIV care. AIDS Patient Care STDS. 2009;23(1):41-49. doi:10.1089/apc.2008.0132. 
69.  Centers for Disease Control and Prevention (CDC). HIV prevalence, unrecognized infection, and 
HIV testing among men who have sex with men--five U.S. cities, June 2004-April 2005. MMWR 
Morb Mortal Wkly Rep. 2005;54(24):597-601. http://www.ncbi.nlm.nih.gov/pubmed/15973239. 
Accessed March 30, 2017. 
70.  Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: 
the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. 
71.  Moore RD, Chaisson RE, Hopkins J. Natural history of HIV infection in the era of combination 
antiretroviral therapy. 1999. 
72.  Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in 
HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect 
Dis. 2011;52(6):793-800. doi:10.1093/cid/ciq243. 
73.  Marrazzo J. Clinical manifestations and diagnosis of Chlamydia trachomatis infections - 
UpToDate. UpToDate. https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-
of-chlamydia-trachomatis-infections. Published 2016. Accessed January 19, 2017. 
74.  Fairley CK, Gurrin L, Walker J, Hocking JS. &quot;Doctor, how long has my Chlamydia been 
there?&quot; Answer: &quot;.... years&quot;. Sex Transm Dis. 2007;34(9):727-728. 
doi:10.1097/OLQ.0b013e31812dfb6e. 
75.  Gottlieb SL, Martin DH, Xu F, Byrne GI, Brunham RC. Summary: The natural history and 
immunobiology of Chlamydia trachomatis genital infection and implications for Chlamydia 
control. J Infect Dis. June 2010:S190-204. http://www.ncbi.nlm.nih.gov/pubmed/20524236. 
Accessed January 18, 2017. 
76.  Darville T, Hiltke TJ. Pathogenesis of genital tract disease due to Chlamydia trachomatis. J Infect 
Dis. 2010;(Supplement 2):S114-25. doi:10.1086/652397. 
77.  Price GA, Bash MC. Epidemiology and pathogenesis of Neisseria gonorrhoeae infection - 
UpToDate. UpToDate. https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-
neisseria-gonorrhoeae-infection. Published 2016. Accessed January 19, 2017. 
78.  Moran JS. Gonorrhoea. BMJ Clin Evid. 2007;2007. 
http://www.ncbi.nlm.nih.gov/pubmed/19454057. Accessed January 18, 2017. 
79.  Yorke JA, Hethcote HW, Nold A. Dynamics and control of the transmission of gonorrhea. Sex 
Transm Dis. 5(2):51-56. http://www.ncbi.nlm.nih.gov/pubmed/10328031. Accessed January 18, 
2017. 
80.  Platt R, Rice PA, McCormack WM. Risk of acquiring gonorrhea and prevalence of abnormal 
adnexal findings among women recently exposed to gonorrhea. JAMA. 1983;250(23):3205-3209. 
http://www.ncbi.nlm.nih.gov/pubmed/6417362. Accessed January 18, 2017. 
81.  Chlamydia - 2015 STD Surveillance. CDC. https://www.cdc.gov/std/stats15/chlamydia.htm. 
Published 2016. Accessed January 19, 2017. 
82.  CDC. Gonorrhea. Centers for Disease Control. doi:10.1097/OLQ.0b013e318286bb53. 
83.  Stenger M, Bauer H, Torrone E. P11.16 Denominators matter: trends in neisseria gonorrhoeae 
incidence among gay, bisexual and other men who have sex with men (gbmsm) in the us – findings 
from the std surveillance network (ssun) 2010–2013. Sex Transm Infect. 2015;91(Suppl 2):A178.3-
A179. doi:10.1136/sextrans-2015-052270.464. 
84.  Beyrer C, Sullivan P, Sanchez J, et al. The increase in global HIV epidemics in MSM. AIDS. 
2013;27(17):2665-2678. doi:10.1097/01.aids.0000432449.30239.fe. 
85.  Lieb S, Fallon SJ, Friedman SR, et al. Statewide Estimation of Racial/Ethnic Populations of Men 
Who Have Sex with Men in the U.S. http://dx.doi.org/101177/003335491112600110. 2011. 
doi:10.1177/003335491112600110. 
86.  Maryland Department of Health and Mental Hygiene. BESURE Study 2004-2014: Baltimore site 
 53 
of National HIV Behavioral Surveillance (NHBS) Survey methods and sample characteristics, 
BESURE 2004-2010 Wave 1 Wave 2 Wave 3 Wave 4 Men who have sex with men (MSM). 
87.  Garofalo R, Herrick A, Mustanski BS, Donenberg GR. Tip of the Iceberg : Young Men Who Have 
Sex With Men , the Internet , and HIV Risk. Am J Public Heal. 2007;97(97):1113-1117. 
doi:10.2105/AJPH.2005.075630. 
88.  Oster AM, Johnson CH, Le BC, et al. Trends in HIV prevalence and HIV testing among young 
MSM: Five United States Cities, 1994-2011. AIDS Behav. 2014;18(SUPPL. 3). 
doi:10.1007/s10461-013-0566-1. 
89.  Beyrer C, Baral SD, Weir BW, Curran JW, Chaisson RE, Sullivan PS. A call to action for 





Curriculum Vitae  
 
Lucas Buyon 
Current Address: 2118 East Pratt Street, Baltimore, MD, 21231                          
Permanent Address: 230 Riverside Drive, Apt 9a, NY, NY 10025                        
lbuyon1@jhu.edu  
Buyon@g.harvard.edu  
Lucas.buyon@gmail.com                                   
                     
 
EDUCATION 
Harvard University, T.H. Chan School of Public Health              Boston, MA 
Department of Immunology and Infectious Diseases        
Doctor of Philosophy (Ph.D.) in Biological Sciences in Public Health                                        Expected January 2023 
 
Johns Hopkins University, Bloomberg School of Public Health         Baltimore, MD                             
Department of Epidemiology                  
Masters of Science (Sc.M.) in Infectious Disease Epidemiology                              May 2017 
 
Emory University, College of Arts and Sciences                             Atlanta, GA 
Bachelors of Science in Biology, Minor in Global Health, Culture and Society                            May 2015  
 
PROFESSIONAL EXPERIENCE 
Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology                    Baltimore, MD 
Research Assistant                                 September 2016 – May 2017 
 Conduct research on using agent-based modeling to simulate outbreaks of HIV and Syphilis among MSM to 
better understand the co-infection epidemiology, and how various interventions will affect outbreak 
dynamics 
 Work under Dr. David Dowdy and Dr. Parastu Kasaie 
 
Ragon Institute of MGH, MIT, and Harvard               Boston, MA 
HIV Epidemiology and Biostatistical Modeling Graduate Intern      May 2016 – August 2016 
 Learned multivariate analysis, dimension reduction, and other machine learning methods, to analyze 
epidemiological and immunological data for HIV research in R software 
 Learned R programming 
 Learned genomic analysis of HIV using MacVector 
 Project focused on longitudinal multivariate analysis of immunologic data to learn what immunological 
factors predicted generation of broadly neutralizing antibodies to HIV. Used nonlinear mixed modeling and 
LASSO techniques to identify these associated factors. 
 
Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology                    Baltimore, MD 
Research Assistant                                 November 2015 – May 2017 
 Assistant at the Johns Hopkins Biological Repository   
 Training in CD4 cell count measurement, HIV viral load measurement, HCV serological testing, PBMC 
harvesting, sample management software and phlebotomy. 
 Help provide laboratory assistance to various HIV cohort studies run by JHSPH. 
 
Johns Hopkins Bloomberg School of Public Health, Department of Environmental Health Science  
      Baltimore, MD 
 Research Assistant                September 2015 – March 2017 
 Assisting on a project to explore the use of dried blood spot (DBS) analysis as a diagnostic tool for toxic 
industrial chemical (TIC) occupational exposures in the dense, urban operational environment; and to 
develop an informatics-informed risk assessment environment for DBS inclusion aimed at recognition and 
control of disaster-related TIC occupational exposures. 
 55 
 Used systematic review software to assist in literature review of DBS applications  
 
The Council For Responsible Genetics            New York, NY 
Policy Research Intern          May 2014 - August 2014 
 Researched and wrote a policy report reviewing high containment laboratory and biosecurity policy in the 
United States, specifically focusing on the San Francisco Bay Area, the growth the biotechnology industry 
there, and the risks associated with this expansion.       
 
The Carter Center                  Atlanta, GA               
Research Assistant                      September 2013- May 2015 
 Orchestrated research into the cost effectiveness of integrating disease control programs 
 Drafting an original manuscript for publication about integrating Trachoma control and Guinea Worm 
Disease eradication programs 
 
Emory University, Rollins School of Public Health               Atlanta, GA                       
Lab Research Assistant           August 2013 – May 2015 
 Conducted research about the epidemiology of meningitis in the Atlanta area 
 Using GIS software to map cases of meningitis over a 20 year period in order to analyze patterns in disease 
transmission  
 Built a Poisson model using SatScan to analyze the temporal and spatial trends of meningitis in the Atlanta 
area to retrospectively identify clusters of disease.  
 
 
The Carter Center                                Atlanta GA 
International Health Programs Intern                          June 2013 - August 2013 
 Assisted in a literature review for a paper on the control of Onchocerciasis and how it’s control helps 
achieve the Millennium Development Goals  
 
 
New York University School of Medicine, Department of Rheumatology       New York, NY 
Intern/ Lab Research Assistant              Summer 2009 and 2010 
 Conducted experiments into researching biomarkers for fetal heart block in lupus patients and mastered lab 
techniques including Western blots, tissue cultures, and assays. 
 Published paper in Rheumatology, titled “A central role of plasmin in cardiac injury initiated by fetal 
exposure to maternal anti-Ro autoantibodies 
TEACHING EXPERIENCE  
Emory University 
Introduction to Global Health, Teaching Assistant             Spring Semester 2015 
 TA for class of 170, duties included grading tests, papers, and homework, and holding office hours and 
review sessions 
 
Johns Hopkins University, Bloomberg School of Public Health 
Pubic Health Impact and Epidemiology of HIV/AIDS, Teaching Assistant           Fall 2016, 1st Quarter 
 TA for class of 70, duties include grading tests, holding office hours, and assisting and providing feedback 
for student presentation 
 
ACTIVITIES 
American Society of Tropical Medicine and Hygiene, Johns Hopkins BSPH Student Assembly Vice President of 
Social and Cultural Affairs, Epidemiology Student Organization, Johns Hopkins Public Health Mentors, Johns 
Hopkins BSPH Committee on Equity, Diversity and Civility member, Pi Kappa Alpha.           




SKILLS AND INTERESTS 
Skills: Lab techniques. Stata Statistical Software, SAS statistical software, R Statistical software, ArcGIS software. 
Excel (intermediate prof.) Microsoft Word, literature review 
Interests: Evolutionary Medicine, Infectious Diseases, Emerging Diseases, Global Health 
 
SELECTED PUBLICATIONS  
1. Dunn, Caitlin, Kelly Callahan, Moses Katabarwa, Frank Richards, Donald Hopkins, P. Craig Withers, Lucas E. 
Buyon, and Deborah Mcfarland. "The Contributions of Onchocerciasis Control and Elimination Programs 
toward the Achievement of the Millennium Development Goals." PLoS Negl Trop Dis PLOS Neglected Tropical 
Diseases 9.5 (2015) 
2. Briassouli, P., M. K. Halushka, J. H. Reed, Y. Molad, K. Fox-Talbot, L. Buyon, E. Guzman, A. Ludomirsky, R. 
M. Clancy, and J. P. Buyon. "A Central Role of Plasmin in Cardiac Injury Initiated by Fetal Exposure to 
Maternal Anti-Ro Autoantibodies." Rheumatology 52.8 (2013): 1448-453.  
 
CONFERNCE PRESENTATIONS 
Lucas Buyon, Randall Slaven, Paul M. Emerson, Jonathan King, Oscar Debrah, Ernesto Ruiz-Tiben, Kelly Callahan. 
Achieving the Endgame: Improving Integrated Case Searches for Guinea Worm Disease and Trachoma to achieve 
Eradication and Elimination Targets. Poster presentation delivered at the American Society of Hygiene and Tropical 
Medicine Annual Meeting, Atlanta, GA, November 2016 
 
